Preemptive interleukin-6 blockade in patients with COVID-19

Area of Science:

• Immunology
• Virology
• Critical Care Medicine

Background:

• Excessive interleukin-6 (IL-6) signaling drives cytokine release syndrome in COVID-19.
• Tocilizumab, an IL-6 receptor antibody, shows promise in severe cases, but its early use is unstudied.
• Blocking IL-6 may prevent severe cytokine storms in COVID-19.

Purpose of the Study:

• To evaluate early tocilizumab administration in hospitalized COVID-19 patients.
• To identify predictors of treatment response and patient outcomes.
• To assess the safety and efficacy of preemptive IL-6 blockade.

Main Methods:

• Consecutive COVID-19 patients with Sequential-Organ-Failure-Assessment (SOFA) score < 3 received tocilizumab.
• Collected serial plasma biomarkers and nasopharyngeal swabs.
• Analyzed clinical data, including demographics, comorbidities, and lab values, to identify response predictors.

Main Results:

• Of 64 eligible patients, 76.6% showed an early favorable response to tocilizumab.
• Predictors of response included gender, SOFA score, neutrophil/lymphocyte ratio, Charlson comorbidity index, and systolic blood pressure.
• Responders had higher SARS-CoV-2 clearance rates and distinct biomarker profiles, correlating with favorable in-hospital outcomes. No deaths or recurrences occurred.

Conclusions:

• Preemptive tocilizumab therapy is safe and effective for hospitalized COVID-19 patients with moderate illness.
• Early IL-6 blockade is associated with favorable outcomes and can be guided by clinical and biological markers.
• This approach may mitigate severe complications of COVID-19.